PubMed

Glycemic variability correlates strongly with postprandial beta-cell dysfunction in a segment of type 2 diabetic patients using oral hypoglycemic agents.

Kohnert KD, Augstein P, Zander E, Heinke P, Peterson K, Freyse EJ, Hovorka R, Salzsieder E.

Diabetes Care. 2009 Jun;32(6):1058-62. Epub 2009 Feb 24.PMID: 19244086 [PubMed - indexed for MEDLINE]Related articlesFree article

Long-term effects of glimepiride or rosiglitazone in combination with metformin on blood pressure control in type 2 diabetic patients affected by the metabolic syndrome: a 12-month, double-blind, randomized clinical trial.

Derosa G, Cicero AF, Gaddi AV, Ciccarelli L, Piccinni MN, Salvadeo S, Pricolo F, Fogari E, Ghelfi M, Ferrari I, Fogari R.

Clin Ther. 2005 Sep;27(9):1383-91.PMID: 16291411 [PubMed - indexed for MEDLINE]Related articles

Mealtime 50/50 basal + prandial insulin analogue mixture with a basal insulin analogue, both plus metformin, in the achievement of target HbA1c and pre- and postprandial blood glucose levels in patients with type 2 diabetes: a multinational, 24-week, randomized, open-label, parallel-group comparison.

Robbins DC, Beisswenger PJ, Ceriello A, Goldberg RB, Moses RG, Pagkalos EM, Milicevic Z, Jones CA, Sarwat S, Tan MH.

Clin Ther. 2007 Nov;29(11):2349-64.PMID: 18158076 [PubMed - indexed for MEDLINE]Related articles

Mathematical modeling shows exenatide improved beta-cell function in patients with type 2 diabetes treated with metformin or metformin and a sulfonylurea.

Mari A, Nielsen LL, Nanayakkara N, DeFronzo RA, Ferrannini E, Halseth A.

Horm Metab Res. 2006 Dec;38(12):838-44.PMID: 17163361 [PubMed - indexed for MEDLINE]Related articles

Inhaled insulin provides improved glycemic control in patients with type 2 diabetes mellitus inadequately controlled with oral agents: a randomized controlled trial.

Weiss SR, Cheng SL, Kourides IA, Gelfand RA, Landschulz WH; Inhaled Insulin Phase II Study Group.

Arch Intern Med. 2003 Oct 27;163(19):2277-82.PMID: 14581245 [PubMed - indexed for MEDLINE]Related articlesFree article

Comparison of insulin with or without continuation of oral hypoglycemic agents in the treatment of secondary failure in NIDDM patients.

Chow CC, Tsang LW, Sorensen JP, Cockram CS.

Diabetes Care. 1995 Mar;18(3):307-14.PMID: 7555472 [PubMed - indexed for MEDLINE]Related articles

Improved glycemic control and enhanced insulin sensitivity in type 2 diabetic subjects treated with pioglitazone.

Miyazaki Y, Mahankali A, Matsuda M, Glass L, Mahankali S, Ferrannini E, Cusi K, Mandarino LJ, DeFronzo RA.

Diabetes Care. 2001 Apr;24(4):710-9.PMID: 11315836 [PubMed - indexed for MEDLINE]Related articlesFree article

One-year treatment with exenatide improves beta-cell function, compared with insulin glargine, in metformin-treated type 2 diabetic patients: a randomized, controlled trial.

Bunck MC, Diamant M, Cornér A, Eliasson B, Malloy JL, Shaginian RM, Deng W, Kendall DM, Taskinen MR, Smith U, Yki-Järvinen H, Heine RJ.

Diabetes Care. 2009 May;32(5):762-8. Epub 2009 Feb 5.PMID: 19196887 [PubMed - indexed for MEDLINE]Related articlesFree article

Metformin plus low-dose glimeperide significantly improves Homeostasis Model Assessment for insulin resistance (HOMA(IR)) and beta-cell function (HOMA(beta-cell)) without hyperinsulinemia in patients with type 2 diabetes mellitus.

Bermúdez-Pirela VJ, Cano C, Medina MT, Souki A, Lemus MA, Leal EM, Seyfi HA, Cano R, Ciscek A, Bermúdez-Arias F, Contreras F, Israili ZH, Hernández-Hernández R, Valasco M.

Am J Ther. 2007 Mar-Apr;14(2):194-202.PMID: 17414590 [PubMed - indexed for MEDLINE]Related articles

United Kingdom Prospective Diabetes Study 24: a 6-year, randomized, controlled trial comparing sulfonylurea, insulin, and metformin therapy in patients with newly diagnosed type 2 diabetes that could not be controlled with diet therapy. United Kingdom Prospective Diabetes Study Group.

[No authors listed]

Ann Intern Med. 1998 Feb 1;128(3):165-75.PMID: 9454524 [PubMed - indexed for MEDLINE]Related articlesFree article

Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group.

Turner RC, Cull CA, Frighi V, Holman RR.

JAMA. 1999 Jun 2;281(21):2005-12.PMID: 10359389 [PubMed - indexed for MEDLINE]Related articlesFree article

Metabolic effects of pioglitazone and rosiglitazone in patients with diabetes and metabolic syndrome treated with glimepiride: a twelve-month, multicenter, double-blind, randomized, controlled, parallel-group trial.

Derosa G, Cicero AF, Gaddi A, Ragonesi PD, Fogari E, Bertone G, Ciccarelli L, Piccinni MN.

Clin Ther. 2004 May;26(5):744-54.PMID: 15220018 [PubMed - indexed for MEDLINE]Related articles

Beneficial effects of insulin on glycemic control and beta-cell function in newly diagnosed type 2 diabetes with severe hyperglycemia after short-term intensive insulin therapy.

Chen HS, Wu TE, Jap TS, Hsiao LC, Lee SH, Lin HD.

Diabetes Care. 2008 Oct;31(10):1927-32. Epub 2008 Jun 12.PMID: 18556343 [PubMed - indexed for MEDLINE]Related articlesFree article

Is type 2 diabetes a different disease in obese and nonobese patients?

Prando R, Cheli V, Melga P, Giusti R, Ciuchi E, Odetti P.

Diabetes Care. 1998 Oct;21(10):1680-5.PMID: 9773730 [PubMed - indexed for MEDLINE]Related articlesFree article

Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes.

Monnier L, Mas E, Ginet C, Michel F, Villon L, Cristol JP, Colette C.

JAMA. 2006 Apr 12;295(14):1681-7.PMID: 16609090 [PubMed - indexed for MEDLINE]Related articlesFree article

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone.

Charbonnel B, Karasik A, Liu J, Wu M, Meininger G; Sitagliptin Study 020 Group.

Diabetes Care. 2006 Dec;29(12):2638-43.PMID: 17130197 [PubMed - indexed for MEDLINE]Related articlesFree article

Changes in amylin and amylin-like peptide concentrations and beta-cell function in response to sulfonylurea or insulin therapy in NIDDM.

Rachman J, Payne MJ, Levy JC, Barrow BA, Holman RR, Turner RC.

Diabetes Care. 1998 May;21(5):810-6.PMID: 9589246 [PubMed - indexed for MEDLINE]Related articlesFree article

Tolerability and efficacy of exenatide and titrated insulin glargine in adult patients with type 2 diabetes previously uncontrolled with metformin or a sulfonylurea: a multinational, randomized, open-label, two-period, crossover noninferiority trial.

Barnett AH, Burger J, Johns D, Brodows R, Kendall DM, Roberts A, Trautmann ME.

Clin Ther. 2007 Nov;29(11):2333-48.PMID: 18158075 [PubMed - indexed for MEDLINE]Related articles

Antithrombotic effects of rosiglitazone-metformin versus glimepiride-metformin combination therapy in patients with type 2 diabetes mellitus and metabolic syndrome.

Derosa G, Gaddi AV, Piccinni MN, Ciccarelli L, Salvadeo S, Peros E, Ghelfi M, Ferrari I, Cicero AF.

Pharmacotherapy. 2005 May;25(5):637-45.PMID: 15899724 [PubMed - indexed for MEDLINE]Related articles

Humalog Mix 25 in patients with type 2 diabetes which do not achieve acceptable glycemic control with oral agents: results from a phase III, randomized, parallel study.

Tîrgovişte CI, Străchinariu R, Farcaşiu E, Milicevic Z, Teodorescu G.

Rom J Intern Med. 2003;41(2):153-62.PMID: 15526500 [PubMed - indexed for MEDLINE]Related articles